CYTK Cytokinetics | $76.10
+0.3% | 8/15/2023 | | Initiated Coverage | $58.00 | Outperform | 00.00% | View details for SVB Securities rating of Cytokinetics (NASDAQ:CYTK) on 8/15/2023 |
DMRA Damora Therapeutics, Inc. Common Stock | $31.80
+2.3% | 8/15/2023 | | Downgrade | | Outperform ➝ Market Perform | 00.00% | View details for SVB Securities rating of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) on 8/15/2023 |
DSGN Design Therapeutics | $15.27
+1.1% | 8/15/2023 | | Downgrade | $6.00 | Outperform ➝ Market Perform | 00.00% | View details for SVB Securities rating of Design Therapeutics (NASDAQ:DSGN) on 8/15/2023 |
EXEL Exelixis | $53.12
+1.5% | 8/8/2023 | | Initiated Coverage | $18.00 | Market Perform | 00.00% | View details for SVB Securities rating of Exelixis (NASDAQ:EXEL) on 8/8/2023 |
IDYA IDEAYA Biosciences | $37.93
+3.8% | 8/8/2023 | | Initiated Coverage | $33.00 | Outperform | 00.00% | View details for SVB Securities rating of IDEAYA Biosciences (NASDAQ:IDYA) on 8/8/2023 |
QTRX Quanterix | $2.68
-8.2% | 8/8/2023 | | Upgrade | $30.00 | Market Perform ➝ Outperform | 00.00% | View details for SVB Securities rating of Quanterix (NASDAQ:QTRX) on 8/8/2023 |
RLAY Relay Therapeutics | $20.61
-0.3% | 8/8/2023 | | Initiated Coverage | | Outperform | 00.00% | View details for SVB Securities rating of Relay Therapeutics (NASDAQ:RLAY) on 8/8/2023 |
NVCR NovoCure | $17.24
-1.7% | 8/4/2023 | | Initiated Coverage | $51.00 | Outperform | 00.00% | View details for SVB Securities rating of NovoCure (NASDAQ:NVCR) on 8/4/2023 |
BLTE Belite Bio | $162.57
-0.4% | 7/26/2023 | | Initiated Coverage | $25.00 | Outperform | 00.00% | View details for SVB Securities rating of Belite Bio (NASDAQ:BLTE) on 7/26/2023 |
NBIX Neurocrine Biosciences | $154.23
-0.2% | 7/24/2023 | | Upgrade | $115.00 ➝ $125.00 | Market Perform ➝ Outperform | 00.00% | View details for SVB Securities rating of Neurocrine Biosciences (NASDAQ:NBIX) on 7/24/2023 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
CYRX CryoPort | $15.09
-1.5% | 7/13/2023 | | Downgrade | $30.00 ➝ $10.00 | Outperform ➝ Market Perform | 00.00% | View details for SVB Securities rating of CryoPort (NASDAQ:CYRX) on 7/13/2023 |
BMY Bristol Myers Squibb | $66.07
+2.2% | 7/10/2023 | | Initiated Coverage | $66.00 | Market Perform | 00.00% | View details for SVB Securities rating of Bristol Myers Squibb (NYSE:BMY) on 7/10/2023 |
MLTX MoonLake Immunotherapeutics | $16.34
-0.1% | 6/26/2023 | | Boost Price Target | $28.00 ➝ $56.00 | | 00.00% | View details for SVB Securities rating of MoonLake Immunotherapeutics (NASDAQ:MLTX) on 6/26/2023 |
PEPG PepGen | $2.91
-4.3% | 6/14/2023 | | Lower Price Target | $33.00 ➝ $28.00 | | 00.00% | View details for SVB Securities rating of PepGen (NASDAQ:PEPG) on 6/14/2023 |
UNH UnitedHealth Group | $394.16
-0.4% | 6/14/2023 | | Lower Price Target | $625.00 ➝ $560.00 | | 00.00% | View details for SVB Securities rating of UnitedHealth Group (NYSE:UNH) on 6/14/2023 |
OCS Oculis | $13.19
+0.4% | 6/12/2023 | | Initiated Coverage | | Outperform | 00.00% | View details for SVB Securities rating of Oculis (NASDAQ:OCS) on 6/12/2023 |
CVAC CureVac | $4.66
| 6/8/2023 | | Initiated Coverage | $13.00 | Outperform | 00.00% | View details for SVB Securities rating of CureVac (NASDAQ:CVAC) on 6/8/2023 |
CSTL Castle Biosciences | $29.03
-3.1% | 6/5/2023 | | Lower Price Target | $50.00 ➝ $35.00 | | 00.00% | View details for SVB Securities rating of Castle Biosciences (NASDAQ:CSTL) on 6/5/2023 |
UHS Universal Health Services | $173.62
+1.8% | 5/26/2023 | | Upgrade | $147.00 ➝ $170.00 | Market Perform ➝ Outperform | 00.00% | View details for SVB Securities rating of Universal Health Services (NYSE:UHS) on 5/26/2023 |
A Agilent Technologies | $148.66
+0.1% | 5/24/2023 | | Lower Price Target | $170.00 ➝ $145.00 | Outperform | 00.00% | View details for SVB Securities rating of Agilent Technologies (NYSE:A) on 5/24/2023 |
ARWR Arrowhead Pharmaceuticals | $87.90
-0.9% | 5/12/2023 | | Downgrade | $40.00 | Outperform ➝ Market Perform | 00.00% | View details for SVB Securities rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 5/12/2023 |
ABCL AbCellera Biologics | $11.12
-0.7% | 5/5/2023 | | Lower Price Target | $16.00 ➝ $15.00 | | 00.00% | View details for SVB Securities rating of AbCellera Biologics (NASDAQ:ABCL) on 5/5/2023 |
AGIO Agios Pharmaceuticals | $34.40
+2.3% | 5/5/2023 | | Lower Price Target | $37.00 ➝ $34.00 | | 00.00% | View details for SVB Securities rating of Agios Pharmaceuticals (NASDAQ:AGIO) on 5/5/2023 |
ALHC Alignment Healthcare | $13.23
-1.7% | 5/5/2023 | | Lower Price Target | $24.00 ➝ $12.00 | | 00.00% | View details for SVB Securities rating of Alignment Healthcare (NASDAQ:ALHC) on 5/5/2023 |
LNTH Lantheus | $100.26
-0.6% | 5/5/2023 | | Boost Price Target | $120.00 ➝ $127.00 | | 00.00% | View details for SVB Securities rating of Lantheus (NASDAQ:LNTH) on 5/5/2023 |
PRVA Privia Health Group | $21.52
+0.1% | 5/5/2023 | | Boost Price Target | $39.00 ➝ $40.00 | | 00.00% | View details for SVB Securities rating of Privia Health Group (NASDAQ:PRVA) on 5/5/2023 |
REGN Regeneron Pharmaceuticals | $810.24
+0.5% | 5/5/2023 | | Lower Price Target | $976.00 ➝ $895.00 | | 00.00% | View details for SVB Securities rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 5/5/2023 |
VIR Vir Biotechnology | $9.49
+1.1% | 5/5/2023 | | Lower Price Target | $43.00 ➝ $42.00 | | 00.00% | View details for SVB Securities rating of Vir Biotechnology (NASDAQ:VIR) on 5/5/2023 |
DHR Danaher | $199.62
-1.5% | 5/1/2023 | | Initiated Coverage | $300.00 | Outperform | 00.00% | View details for SVB Securities rating of Danaher (NYSE:DHR) on 5/1/2023 |
LLY Eli Lilly and Company | $1,227.11
+3.7% | 5/1/2023 | | Boost Price Target | $410.00 ➝ $458.00 | | 00.00% | View details for SVB Securities rating of Eli Lilly and Company (NYSE:LLY) on 5/1/2023 |
HUM Humana | $382.13
-0.6% | 4/27/2023 | | Lower Price Target | $640.00 ➝ $600.00 | | 00.00% | View details for SVB Securities rating of Humana (NYSE:HUM) on 4/27/2023 |
ALVR AlloVir | $3.96
-2.9% | 4/26/2023 | | Boost Price Target | $368.00 ➝ $437.00 | | 00.00% | View details for SVB Securities rating of AlloVir (NASDAQ:ALVR) on 4/26/2023 |
PRTA Prothena | $8.71
-1.9% | 4/24/2023 | | Initiated Coverage | $80.00 | Outperform | 00.00% | View details for SVB Securities rating of Prothena (NASDAQ:PRTA) on 4/24/2023 |
BBIO BridgeBio Pharma | $82.98
+3.9% | 4/13/2023 | | Boost Price Target | $25.00 ➝ $27.00 | Outperform | 00.00% | View details for SVB Securities rating of BridgeBio Pharma (NASDAQ:BBIO) on 4/13/2023 |
FDMT 4D Molecular Therapeutics | $14.72
+1.2% | 4/13/2023 | | Lower Price Target | $14.00 ➝ $13.00 | Market Perform | 00.00% | View details for SVB Securities rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 4/13/2023 |
ARWR Arrowhead Pharmaceuticals | $87.90
-0.9% | 4/12/2023 | | Upgrade | $21.00 ➝ $35.00 | Market Perform ➝ Outperform | 00.00% | View details for SVB Securities rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 4/12/2023 |
CORT Corcept Therapeutics | $118.10
+0.8% | 4/11/2023 | | Initiated Coverage | $25.00 | Market Perform | 00.00% | View details for SVB Securities rating of Corcept Therapeutics (NASDAQ:CORT) on 4/11/2023 |
IPHA Innate Pharma | $2.07
-8.4% | 4/10/2023 | | Boost Price Target | $9.00 ➝ $10.00 | | 00.00% | View details for SVB Securities rating of Innate Pharma (NASDAQ:IPHA) on 4/10/2023 |
REGN Regeneron Pharmaceuticals | $810.24
+0.5% | 3/27/2023 | | Upgrade | $834.00 ➝ $976.00 | Market Perform ➝ Outperform | 00.00% | View details for SVB Securities rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 3/27/2023 |
INCY Incyte | $123.47
0.0% | 3/24/2023 | | Upgrade | $61.00 | Underperform ➝ Market Perform | 00.00% | View details for SVB Securities rating of Incyte (NASDAQ:INCY) on 3/24/2023 |
Trump’s “BIG MISTAKE” stock is still dirt cheap (Ad) A U.S. energy producer operating across 3.7 million acres now pumps roughly 143,299 barrels of oil and 467 million cubic feet of natural gas daily, yet the entire business is valued at just 8 billion despite generating 3.2 billion in operating income.
Wall Street institutions already hold about 88 percent of shares, and management has authorized a 40-million-share buyback, but most individual investors still don't know the company's name.
As AI data centers strain the power grid, this producer's natural gas output could become increasingly valuable. Watch the full presentation on this overlooked energy stock now |
PTCT PTC Therapeutics | $72.63
-0.3% | 3/17/2023 | | Initiated Coverage | $48.00 | Market Perform | 00.00% | View details for SVB Securities rating of PTC Therapeutics (NASDAQ:PTCT) on 3/17/2023 |
HALO Halozyme Therapeutics | $104.89
+1.8% | 3/16/2023 | | Downgrade | $42.00 | Outperform ➝ Market Perform | 00.00% | View details for SVB Securities rating of Halozyme Therapeutics (NASDAQ:HALO) on 3/16/2023 |
FULC Fulcrum Therapeutics | $3.87
+0.8% | 3/10/2023 | | Lower Price Target | $18.00 ➝ $10.00 | | 00.00% | View details for SVB Securities rating of Fulcrum Therapeutics (NASDAQ:FULC) on 3/10/2023 |
ARGX argenex | $992.99
+0.5% | 3/3/2023 | | Boost Price Target | $430.00 ➝ $435.00 | | 00.00% | View details for SVB Securities rating of argenex (NASDAQ:ARGX) on 3/3/2023 |
AHCO AdaptHealth | $5.82
+0.2% | 3/1/2023 | | Lower Price Target | $30.00 ➝ $23.00 | | 00.00% | View details for SVB Securities rating of AdaptHealth (NASDAQ:AHCO) on 3/1/2023 |
MDRX Veradigm | $4.96
-0.7% | 3/1/2023 | | Lower Price Target | $24.00 ➝ $17.00 | | 00.00% | View details for SVB Securities rating of Veradigm (NASDAQ:MDRX) on 3/1/2023 |
GPCR Structure Therapeutics | $53.53
-0.4% | 2/28/2023 | | Initiated Coverage | $33.00 | Outperform | 00.00% | View details for SVB Securities rating of Structure Therapeutics (NASDAQ:GPCR) on 2/28/2023 |
IRON Disc Medicine | $80.20
+0.2% | 2/28/2023 | | Initiated Coverage | $36.00 | Outperform | 00.00% | View details for SVB Securities rating of Disc Medicine (NASDAQ:IRON) on 2/28/2023 |
MRNA Moderna | $62.96
-2.3% | 2/24/2023 | | Downgrade | $111.00 ➝ $93.00 | Market Perform ➝ Underperform | 00.00% | View details for SVB Securities rating of Moderna (NASDAQ:MRNA) on 2/24/2023 |
NKTR Nektar Therapeutics | $73.64
+1.3% | 2/24/2023 | | Lower Price Target | $75.00 ➝ $45.00 | | 00.00% | View details for SVB Securities rating of Nektar Therapeutics (NASDAQ:NKTR) on 2/24/2023 |
IONS Ionis Pharmaceuticals | $59.62
+1.7% | 2/23/2023 | | Lower Price Target | $34.00 ➝ $27.00 | | 00.00% | View details for SVB Securities rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 2/23/2023 |
TDOC Teladoc Health | $6.45
-1.4% | 2/23/2023 | | Upgrade | $34.00 | Market Perform ➝ Outperform | 00.00% | View details for SVB Securities rating of Teladoc Health (NYSE:TDOC) on 2/23/2023 |
ABBV AbbVie | $259.02
+3.5% | 2/10/2023 | | Upgrade | $135.00 ➝ $153.00 | Underperform ➝ Market Perform | 00.00% | View details for SVB Securities rating of AbbVie (NYSE:ABBV) on 2/10/2023 |
CI Cigna Group | $278.96
+1.3% | 2/8/2023 | | Lower Price Target | $335.00 ➝ $309.00 | | 00.00% | View details for SVB Securities rating of Cigna Group (NYSE:CI) on 2/8/2023 |
VRTX Vertex Pharmaceuticals | $528.19
+2.5% | 2/8/2023 | | Lower Price Target | $374.00 ➝ $365.00 | | 00.00% | View details for SVB Securities rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 2/8/2023 |
AMGN Amgen | $425.28
+1.4% | 2/2/2023 | | Lower Price Target | $282.00 ➝ $267.00 | | 00.00% | View details for SVB Securities rating of Amgen (NASDAQ:AMGN) on 2/2/2023 |
META Meta Platforms | $543.82
-4.4% | 2/2/2023 | | Boost Price Target | $220.00 ➝ $255.00 | Outperform | 00.00% | View details for SVB Securities rating of Meta Platforms (NASDAQ:META) on 2/2/2023 |
DNLI Denali Therapeutics | $24.31
-0.2% | 1/30/2023 | | Initiated Coverage | $50.00 | Outperform | 00.00% | View details for SVB Securities rating of Denali Therapeutics (NASDAQ:DNLI) on 1/30/2023 |
BHVN Biohaven | $13.59
-6.0% | 1/24/2023 | | Initiated Coverage | $24.00 | Outperform | 00.00% | View details for SVB Securities rating of Biohaven (NYSE:BHVN) on 1/24/2023 |
